';
Science & Research

WE DO OUR PART

We cordially care for people. From employees to doctors and patients: We take our responsibility seriously. Specialized in sex hormones, we support respective projects and researches in order to drive forward progress and efficiency in indication areas, providing patients with the best possible therapies.

Reproductive Medicine and Andrology at the Westphalians Wilhelm’s University Muenster

In the period between the 1st of December 2016 up until the 31st of December in 2019, a registry study is carried out by the Centre for Reproductive Medicine and Andrology at the Westphalians Wilhelm’s University Muenster (person in authority: Professor Zitzmann). DR. KADE / BESINS assists in the academic work on the effects of testosterone treatment on hypogonadal men on haematosis and other parameters, including improvement of symptoms and discomfort. So far, there is an assumption that treatment with testosterone gel results to a lesser extent in excessive increases in haemoglobin and haematocrit compared to injection treatments.

University Medical Centre for Gynaecological Endocrinology

In the Department of Gynaecological Endocrinology at the University Clinic for Obstetrics and Gynaecology at the Inselspital Bern (person in authority: Professor Stute), DR. KADE / BESINS is currently supporting a research project on the influence of oral progesterone treatment on the energy consumption of menopausal women. It is assumed that progesterone – not least due to its thermogenic effect – might increase energy consumption. Yet, there is no fixed time frame for the study.

Department of Women’s Health at the University Hospital Tuebingen

In the Department of Women‘s Health at the University Hospital Tuebingen (person in authority: Prof. Seeger), it was from 1st of January 2016 until the 31st of July 2017 that DR. KADE / BESINS supported investigations on specific progesterone receptor membrane components (PGRMC1) in women, both with and without breast and ovarian cancer, aiming to clarify whether PGRMC1 is increasingly formed in women with gynaecological tumours.